Feature | SCAI | May 08, 2019

Late-breaking Interventional Cardiology Presentations at SCAI 2019

Here is the list of featured clinical research at the Society for Cardiovascular Angiography and Interventions annual meeting

Khaldoon Alaswad, M.D., FSCAI, right, during a chronic total occlusion (CTO) case in his lab at Henry Ford Hospital, Detroit. He is presenting in several SCAI 2019 sessions.  SCAI 2019 late breaking sessions, SCAI featured research sessions.

Khaldoon Alaswad, M.D., FSCAI, right, during a chronic total occlusion (CTO) case in his lab at Henry Ford Hospital, Detroit. He is presenting in several SCAI 2019 sessions.  


May 8, 2019 — The Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions will take place May 19-22, 2019 at the Cosmopolitan of Las Vegas in Las Vegas, Nev. The biggest news will be from the featured clinical research sessions that highlight the latest advances in interventional cardiology. Here is at the list of sessions:

 

Featured Clinical Research, Part I 
   • A Risk Score to Predict Post-Discharge Bleeding Among Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: BRIC-ACS Study, presented by Yundai Chen.

   • AVIATOR-2: Antithrombotic Strategy Variability in Atrial Fibrillation and Obstructive Coronary Disease Revascularized with Percutaneous Coronary Intervention Registry, presented by Ridhima Goel, M.B.B.S

   • Plaque Regression and Endothelial Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), presented by Subhash Banerjee, M.D., FSCAI.

   • Superior Vena Caval Occlusion in Acute Decompensated Heart Failure: First-in-Human Experience, presented by Navin K. Kapur, M.D., FSCAI.

   • Improved Outcomes May Be Associated With the Use of Shock Protocols: Updates From the National Cardiogenic Shock Initiative, presented by Mir Basir, D.O.

 

Featured Clinical Research, Part II
   • A Global Registry of Fractional Flow Reserve (FFR)-Guided Management During Routine Clinical Procedures, presented by Erick Schampaert, M.D.

   • Derivation and Validation of Pd/Pa for the Assessment of Residual Ischemia Post Intervention - A Prospective All Comer Registry, presented by Abdul Hakeem, M.D., FSCAI.

   • First-in-Human Study of the Saranas Early Bird Bleed Monitoring System for the Detection of Endovascular Procedure Related Bleeding Events, presented by Philippe Genereux, M.D.

   • Impact of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation on Patients With Chronic Kidney Disease: Results From ULTIMATE Trial, presented by Junjie Zhang, M.D., FSCAI.

   • Vascular Closure Device Type Impacts Bleeding and Vascular Complications After TAVR: Results From the BRAVO 3 Randomized Trial, presented by David A. Power, MB BCh. 

 

Other SCAI 2019 News:

Cardiac Cath Lab Economics Consensus Statement Released by SCAI and ACVP

SCAI Releases New Consensus Document on Classification Stages of Cardiogenic Shock

Philips Launches IntraSight Interventional Applications Platform

Impella SmartAssist Platform Launches at SCAI

Cordis Announces U.S. Launch of Radial 360 Portfolio

For more information on these or other sessions, visit: www.scai.org/SCAI2019

 

Other Recent Late-breaking Cardiology Trials:

SCAI 2018 Late-breaking Clinical Trials

ACC 2019 Late-breaking Presentations

TCT 2018 Late-breaking Cardiovascular Clinical Trials

EuroPCR 2018 Late-breaking Trials in Interventional Cardiology

Heart Rhythm 2018 Late-breaking Studies

ACC 2019 Late-breaking Presentations

TCT 2019 Late-breaking Presentations

Late-breaking Interventional Cardiology Presentations at SCAI 2019

American Heart Association 2018 Late-breaking Trials

VIVA 2019 Late-breaking Clinical Trials

 

 

#SCAI2019  #SCAI19  #SCAI


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now